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Summary
Community viral load (CVL), an aggregation of individual viral loads of HIV-infected persons 
within a defined community, has been proposed as a useful metric for monitoring HIV treatment 
uptake and quantifying its impact on transmission. The first publications regarding CVL appeared 
in 2009 and the metric was subsequently incorporated into the United States National HIV/AIDS 
Strategy. Although CVL is intuitively appealing, it has several theoretical limitations and biases 
that require further evaluation. These limitations and biases can be categorized in four areas 
related to: 1) selection and measurement issues in calculating CVL among HIV-infected persons, 
2) the importance of HIV prevalence in determining the potential for ongoing HIV transmission, 
3) interpretation of CVL and its impact on ongoing HIV transmission in a community, and 4) the 
ecological fallacy (ecological bias). These potential issues deserve careful assessment as CVL is 
being considered as a public health metric to assess the impact of HIV care on prevention.
Community viral load (CVL) is a recently developed metric that has been evaluated in 
attempts to quantify a population’s exposure to antiretroviral therapy (ART) and assess the 
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effect of treating HIV-infected persons on HIV transmission.1–4 CVL is “an aggregate 
biological measure of viral load for a particular geographic location or community,”1 
typically calculated as the arithmetic mean, geometric mean (the average of the base 10 
logarithm), median, or sum of the highest or most recent VL of all reported HIV-infected 
persons with available viral load measurements in a particular population in a given time 
period.1,3,4 The central hypothesis underlying the use of CVL is that as ART coverage 
increases, greater numbers of HIV-infected persons will be virologically suppressed, leading 
to reduced CVL, and consequently, reduced incidence of HIV infection in the general 
population.1 CVL has two potential uses: 1) a research measure of the potential for ongoing 
HIV transmission within a community, and 2) a surveillance metric for monitoring ART 
uptake and effectiveness. Underlying both of these uses is the assumption that CVL is a key 
determinant of HIV incidence within a community.
The uptake of this measure has been rapid. Since its introduction in British Columbia2,3 and 
San Francisco1, CVL has been used in Washington, DC4, Uganda5, and elsewhere.6 Lower 
CVL was modestly associated with reductions in measures of new HIV diagnoses over time 
in some studies,1–3 but not in others.4 Although ecological in nature and limited by the use 
of new HIV diagnoses as a proxy for HIV incidence,7 these associations have been 
interpreted as being driven by the individual-level effect of ART on HIV transmission.1,3 
Motivated by these studies, CVL has been incorporated into requests for proposals from the 
U.S. National Institutes of Health8 and guidance from the U.S. Centers for Disease Control 
and Prevention (CDC).9,10 More importantly, the U.S. National HIV/AIDS Strategy has 
called for reducing CVL as an “innovative solution” that “may help reduce the number of 
new HIV infections in specific communities that may, in turn, reduce disparities in HIV 
infection.”11
The concept of CVL, including its incorporation into CDC recommendations and US 
National HIV/AIDS strategy, has had several positive effects. Foremost, surveillance 
programs in the U.S., Europe, and elsewhere have become sensitized to the importance of 
the infectiousness of the HIV-infected individual. Monitoring and surveillance programs 
have been mobilized to identify persons in and out of care and expand efforts to capture HIV 
testing, treatment, and viral load data. This increased attention to monitoring will 
undoubtedly increase the likelihood of truly applying public health principles to the HIV 
epidemic.12
However, the increased attention to HIV surveillance necessitates a careful examination of 
the utility of proposed metrics. Although CVL and HIV incidence are plausibly related 
causally, the data available to estimate CVL and its link to incidence are limited. Some of 
these limitations have been stated,1,7,13 but the rapid encouragement to implement CVL as a 
priority measure suggests that some of these limitations may not have been fully 
appreciated. Here, we address several limitations and potential biases of CVL in four general 
categories related to: 1) selection and measurement issues in calculating CVL among HIV-
infected individuals, 2) the importance of HIV prevalence in determining ongoing HIV 
transmission, 3) interpretation of CVL and its impact on ongoing transmission in a 
community, and 4) the ecological fallacy (ecological bias). Each of these issues relates to the 
use of CVL for estimating the potential for ongoing transmission within a community; the 
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first issue also relates to the use of CVL as a metric for monitoring ART uptake. Our goal is 
to encourage cautious use of aggregate viral load metrics, and to advocate development of 
alternative population metrics and study designs.
Issues with Selection and Measurement
Non-representative samples of the HIV-infected population
Aggregate viral load measures depend on a person’s diagnosis, engagement in care, 
measurement of his/her viral load, and reporting of that viral load to a public health 
authority. In many settings, a significant proportion of HIV-infected persons are not linked 
to or engaged in care. The HIV care cascade, reflecting HIV diagnosis, linkage to care, 
retention in care, and appropriate treatment, reflects the incompleteness of HIV care.14–16 In 
2010 in the United States, an estimated 1,178,350 persons had HIV infection, but only 
61.6% were linked to care and only 40.8% retained in HIV care.16 Consequently, any 
estimate of the CVL based on persons linked to and/or retained in care will be based on a 
subset of the HIV-infected population.14–16
A sample of persons derived only from those in care will be a non-random subset of the total 
HIV-infected population. An in-care-only population excludes persons with undiagnosed 
HIV infection and persons with known HIV status who are not engaged in care. The not-in-
care population cannot receive the benefits of ART and therefore will have higher viral 
loads than the in-care population included in the CVL calculation (Figure 1), resulting in a 
biased estimate of CVL.
Even if testing and medical care coverage of the HIV-infected population was considerably 
enhanced, CVL would remain underestimated, because persons with acute and early HIV 
infection are missed with routine HIV testing in most settings and therefore will not be 
identified and linked to care.17–21 Acute/early HIV infection, reflecting the first few weeks 
to months of infection, is associated with enhanced transmissibility,22 due to markedly 
elevated viral loads23,24 and the characteristics of the initial infecting virus.25 The 
proportion of ongoing transmission attributable to acute/early HIV infection will vary by 
setting, depending on the local characteristics of the epidemic. Estimates of the transmission 
attributable to acute/early HIV have varied,26 but was as high as 38% in one African setting 
with an established epidemic.27 Detection of acute/early infection requires special efforts, 
such as pooled testing of ELISA negative specimens with HIV RNA PCR or use of p24 
antigen ELISAs in combination with traditional antibody ELISAs.17,19 However, even if 
these alternative testing approaches were widely used, many, if not most, persons with 
acute/early infection would remain undetected, because detection requires recently infected 
persons to actively seek testing. Consequently, even with regular HIV testing and linkage to 
care, CVL measured through the health system will always underestimate the “true” CVL 
(i.e. population viral load) because the high viral loads of acute cases are excluded.
In its recent guidance for monitoring CVL, the CDC has acknowledged the issue of selection 
bias.9,10 The CDC has proposed a series of aggregate viral load measures reflecting different 
levels of data availability in the HIV care cascade, including “population viral load”, 
“community viral load”, “in-care viral load”, and “monitored viral load” (Figure 2). (Note: 
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We have used the term community viral load to broadly represent these aggregate viral load 
measures, except where explicitly stated in the text.) Although the definition of these 
measures partially addresses the issue of selection bias due to limited availability of data for 
persons not engaged in care, the magnitude of the bias and the utility of these various 
measures are not directly addressed. Furthermore, none of these proposed measures accounts 
for the relative size of the HIV-infected population (i.e., the prevalence), as discussed in the 
next section.
To demonstrate the potential impact of selection bias related to the HIV care cascade and 
acute/early HIV infection, we conducted a simple exercise using plausible estimates of the 
proportion of the HIV-infected population and mean viral loads present at each step of the 
cascade (Figure 3). Based on CDC estimates of the HIV care cascade, the measured CVL 
(i.e. monitored viral load) in a typical US setting may underestimate the true population viral 
load by about 50%. In a best-case scenario, such as in San Francisco, where greater 
proportions of the HIV-infected population are aware of their infection status and in care 
(and thus captured by CVL measures), the underestimation may be smaller, approximately 
15%.
The issue of selection bias could be addressed with a population-based survey in a clearly 
defined target population of all persons in a community, including those with and without 
known HIV infection and measurement of viral loads in infected persons. Such a random 
sample would overcome the biased sample associated with engagement in care and would 
provide a more accurate estimation of the distribution of the viral loads in the community. 
However, a survey-based approach is unlikely to be used routinely for surveillance purposes 
because of the expense, especially in low prevalence settings, where extremely large 
samples would be needed. Furthermore, acute HIV cases will be missed with routine HIV 
tests, unless testing is completed using HIV RNA testing (e.g. pooling).19 Finally, even if 
selection bias is substantially reduced, several challenges with CVL remain, as described 
below.
Sampling concerns within persons - Instability of viral loads within persons over time
Viral loads are dynamic within persons over time. While the goal of treatment is long-term 
suppression, some treated persons experience intermittent28 or long-term virological 
failure.29 CVL calculation has typically used a single viral load from each patient collected 
during the course of a given calendar year.1,3,4 Some persons have multiple viral loads, 
others one, and some none. Whether single or multiple viral loads are available, the time at 
which the available or selected viral load was measured could influence the accuracy and 
appropriateness of the CVL measure, both for predicting ongoing transmission and 
monitoring ART uptake. For example, any viral load measurement recorded while a person 
is on treatment may underestimate his/her overall contribution to CVL in the course of a 
given year if he/she subsequently drops out of care. Similar issues arise for those entering 
care, as viral loads before entering care, which will not routinely contribute to aggregate 
viral load measurements, will be higher on average than those recorded after entering care 
and initiating ART.
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The Uninfected Population and HIV Transmission - Prevalence is important
Any population (or “community”) for which we wish to understand HIV transmission will 
comprise both HIV-infected and HIV-uninfected persons. HIV incidence will depend not 
only on the viral loads of infected persons, but also on the relative sizes of the infected and 
uninfected populations (i.e. HIV prevalence), and the rates and patterns of contact between 
them. To date, CVL measures have not considered the impact of HIV prevalence within the 
communities under observation.1–4
Consider two communities with the same population size but markedly different prevalence 
of HIV infection. In Community A, the prevalence of HIV infection is 5%. In Community 
B, the prevalence of HIV infection is 0.1%. Assume that in each community the mean CVL 
is 2000 copies/ml and is measured perfectly among all infected people. Also, assume that 
average contact rates are the same. Despite the equal CVL across communities, the HIV 
incidence rate will be substantially greater in the community with higher prevalence because 
the incidence rate is approximately equal to the product of the prevalence of infection, the 
average contact rate, and per-contact transmission probability.30
CVL interpretation – Estimating the potential for ongoing transmission in a 
community
Within any given population, the distribution of viral loads is likely to be multimodal 
(Figure 1). Among those in care, many persons will have achieved virological suppression, 
which will be reflected by a large peak below the limits of detection. The viral loads of the 
remaining persons in care will tend to be log-normally distributed.31 For persons out of care, 
the distribution is expected to be broader with a tail extending far to the right reflecting 
persons with especially high viral loads, including those with acute/early HIV infection. The 
shape of this composite distribution (Figure 1) presents a problem for any single summary 
measure of viral loads, including the arithmetic mean, geometric mean, median, or sum.
An aggregate viral load metric is a suboptimal measure of the potential for ongoing 
transmission in a community, even if all viral loads in a community are available. Consider 
two, extreme examples of populations with identical HIV prevalence and 10 HIV-infected 
persons. In each population, the viral loads for all HIV-infected persons are known and the 
mean CVL is 10,000 copies/ml (Figure 4). In Population A, the 10 HIV-infected persons 
have viral loads ranging from 2,000 to 20,000 with a mean of 10,000 copies/ml. In 
Population B, 9 of the 10 HIV-infected persons have undetectable viral loads and the tenth 
person has a viral load of 100,000 copies/ml. Although the CVL based on the mean or sum 
is identical, the likelihood of ongoing transmission in these communities is likely not the 
same.
In addition to his/her viral load, the number of secondary transmissions attributable to any 
person depends on his/her sexual behavior and the properties of his/her sexual network. In 
Population B above (Figure 4), if the one person with the viral load of 100,000 copies/ml is 
monogamous with an HIV-infected partner (Figure 4, C), the probability of secondary 
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transmissions will be considerably lower than if s/he has multiple HIV-uninfected partners 
(Figure 4, D). Similar variations can be considered with Population A.
The sexual networks of these two populations further affect the likelihood of ongoing 
transmission in the community. If the sexual networks are densely connected between HIV-
infected and -uninfected persons, transmission is facilitated.32 But, if the networks are 
predominated by pairs of stable couples with few inter-couple links, ongoing transmission 
will be restricted.33 Overall, transmission is critically determined by a combination of 
several factors including the sexual behavior, network positions and viral loads of the HIV-
infected persons in a population. In other words, in communities with similar mean viral 
loads, substantial variation in transmission patterns is not just possible, but expected. 
Consequently, the relationship between CVL and HIV incidence will vary across settings, 
reducing the utility of CVL as a universal measure of the likelihood of ongoing transmission 
within a community.
CVL and the ecological fallacy
In epidemiology, ecological data are useful for assessing group-level effects that occur 
above and beyond the expected contribution of individual-level effects. For example, for 
many infectious diseases, the group-level effects may be greater than expected based on 
individual data, due to interdependence of transmission events.34 However, using ecological 
data alone to determine individual-level causality is problematic.30 The attribution of causal 
effects at the individual level based on group-level observations is referred to as the 
ecological fallacy.30
Most studies relating CVL to measures of HIV transmission have noted the limitation of 
using ecological data, but have still interpreted the observed ecological associations as being 
driven solely by the individual-level effects of ART on HIV transmission.1,3 However, 
reduced HIV diagnosis rates in areas with lower CVL cannot be attributed with certainty to 
reduced transmission from persons with lower viral loads.
Although ecological associations between CVL and new HIV diagnoses may be partially 
driven by reduced biological infectiousness of those on treatment, these associations are also 
determined by additional factors at both the individual and population levels. Improved 
treatment services may be paired with other HIV prevention efforts that may have a 
population-level effect. For example, the population benefits of increased ART use among 
injection drug users cannot easily be dissociated from the beneficial impact of needle 
exchange and other programs targeted to this population.3,35,36 The ecological level of these 
analyses without data to link to individual transmission events is insufficient to determine 
whether viral suppression is responsible for reduced incidence, even if selection bias in CVL 
measurements were adequately addressed and an appropriate summary of the distribution 
was used.
Alternative metrics for consideration
Many of the shortcomings of CVL are due to the limitations of routinely available public 
health data. Surveillance data vary in quality, depending on the data sources and the 
Miller et al. Page 6













completeness of data capture. Many alternative metrics will be limited similarly. 
Nonetheless, improvements may be possible, even if a perfect measure is unavailable.
One alternative measure is the proportion of persons in the entire population with a viral 
load greater than a pre-specified threshold, such as any detectable viral load (“detectable 
viral load proportion”).37 Other examples of this type of proportion include the proportion of 
persons with VL >400 or proportion of persons with VL >1000. The rationale for this 
measure has three key components: 1) transmission will occur almost exclusively in persons 
with measurable viral loads, 2) the HIV infection prevalence is incorporated into the 
measure directly, and 3) persons not in care can be assumed to have a detectable viral load. 
This third point is critical, but requires that the community have a reasonably valid estimate 
of the HIV infection prevalence in the community. Reasonable prevalence estimates will be 
available in some settings, but not others.
From a surveillance perspective, a combination of metrics may be necessary to obtain a 
complete description of the status of the HIV epidemic in a community. Considering 
treatment for an individual’s own benefit and treatment for the potential prevention of 
transmission will require monitoring the full cascade of HIV testing, diagnosis, engagement 
in care, retention in care, and viral suppression. Incorporating aspects of these stages of the 
care cascade into a composite metric may provide a useful measure for enhanced 
monitoring.
Conclusions
We have entered a new and exciting phase of HIV prevention. The potential for HIV 
treatment to prevent HIV transmission is substantial and promising. As the impact of 
broader and earlier ART use on HIV incidence in a population undergoes further study, the 
value of CVL as a routine measure of a community’s ART uptake and potential for ongoing 
transmission will be examined further. However, in practice, few areas currently have 
sufficient engagement and retention in care to estimate population-level aggregate viral load 
measures accurately and meaningfully. Even with adequate coverage across the HIV care 
cascade, aggregate viral load measures are imperfect metrics of ART uptake due to issues 
related to acute/early HIV infection and intra-individual viral load variations. The use of 
CVL as a measure of potential ongoing transmission in a community is complicated by 
those same issues, as well as those related to HIV prevalence, sexual behavior, sexual 
networks, and the ecological fallacy. The relative strengths and weaknesses of CVL and 
other proposed metrics for monitoring the impact of ART on the HIV epidemic must be 
addressed in future studies including observational studies, community randomized trials, 
and mathematical modeling.
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Figure 1. Schematic representation of viral load distribution in a hypothetical HIV-infected 
population
Any population of HIV-infected persons will consist of individuals with undetectable viral 
loads (red curve), individuals with detectable viral loads who are receiving treatment (blue 
curve), and individuals with detectable viral loads who are not receiving treatment (green 
curve). Diagram provides qualitative representation of expected viral load distribution; 
actual distribution will be specific to a particular population.
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Figure 2. Relationship between population subgroups and CDC-defined aggregate measures of 
viral load
In the set of concentric circles representing an entire hypothetical population (gray) and 
various population sub-groups (each a different color), subpopulations represented by a 
given, smaller circle belong to all groups represented by larger, surrounding circles. The size 
of each circle is proportional to the size of a given sub-group, assuming 15% HIV 
prevalence (hypothetical), 79% of cases diagnosed,14 50% of diagnosed cases in care,14 and 
75% of cases in care with viral loads available (hypothetical). For each CDC-defined viral 
load metric listed on the right side of the figure, the origin of the corresponding arrow 
indicates the sub-population (including all smaller sub-populations) contributing to the 
metric. Notably, none of the proposed metrics accounts for the size of the uninfected 
population (i.e., 1 – prevalence).
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Figure 3. Estimated mean values of true population viral load, community viral load, and 
monitored viral load as defined by CDC
Population viral load = mean viral load among all HIV-infected individuals (theoretical; 
currently unobserved). Monitored viral load = estimated mean viral load as measurable in 
settings with VL data available only for persons in care. Community viral load = estimated 
mean viral load for persons in and out of care, excluding undiagnosed, as measured in a 
best-case setting (based on San Francisco data). A detailed description of the methods used 
in generating the figure is contained in the supplemental material. Briefly, figure 
assumptions and calculations were based on published estimates of the proportions of HIV-
infected populations in key subgroups along the HIV care cascade (ref [1] for San Francisco, 
ref [14] for the US overall), proportions of infection-unaware persons with acute infection 
[18, 19], and mean viral loads in each sub-group [1, 18, 20].
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Figure 4. Representation of populations with identical prevalence and community viral loads, 
but different potential for ongoing transmission
A) Viral loads distributed between 2000 and 20,000; B) Viral loads <50 in 9 persons and 
100,000 in 10th person; C) Population B with person with high viral load in monogamous 
relationship with HIV-infected, suppressed person; D) Population B with person with high 
viral load with multiple uninfected partners.
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